Paradigms secondary endpoints successfully met
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigm (PAR) Updated Investor Presentation
- S&P DJI Announces March 2019 Quarterly Rebalance
- Paradigms orphan phase 2/3 clinical program progresses
- Paradigms supplementary phase 2B data
- Presentation of phase 2 clinical trial results
Later from Paradigm Biopharmaceuticals
- Paradigm launches a$77.9M capital raise
- Paradigm updated corporate presentation
- Paradigm Confirms Capital Raise Commitments
- PAR Accelerated Non-Renounceable Rights Issue Offer Booklet
- Completion of Institutional Entitlement Offer
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals